Innovair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone acts on glucocorticoid receptors in airway cells, suppressing inflammatory pathways and decreasing swelling. Formoterol binds to beta2‑adrenergic receptors on airway smooth muscle, raising cyclic AMP levels and producing sustained bronchodilation. Together they control inflammation while maintaining airway patency.

The prescribed dose of Innovair Nexthaler is determined by the treating physician based on the patient’s age, disease severity, and response to therapy. The prescriber will instruct the patient on the number of inhalations per day and the timing of each dose.

Safety data for Innovair Nexthaler in pregnancy and lactation are limited. The decision to use it should be made by a healthcare professional after weighing the potential benefits for the mother against any possible risks to the fetus or infant.

To order Innovair Nexthaler, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Innovair Nexthaler combines a corticosteroid and a long‑acting beta2‑agonist in a dry‑powder device, offering once‑daily dosing for many patients. Compared with separate inhalers or combination products that use metered‑dose sprays, it may provide more consistent dosing and eliminates the need for propellants, though device preference varies by individual.

Store Innovair Nexthaler at room temperature, below 25 °C, in its original packaging. Keep the device away from moisture and direct sunlight. Do not expose it to extreme heat or freeze it, as this could affect the powder’s integrity and dosing performance.

The patient inhales the powder through the mouthpiece of the Nexthaler device after a full exhalation, then holds their breath for several seconds to allow the medication to reach the lungs. The inhaler should be primed according to the manufacturer’s instructions before first use.

Serious risks include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, cardiovascular events like tachycardia or arrhythmia, and systemic effects from the corticosteroid component such as hyperglycemia or adrenal suppression, especially with high‑dose or prolonged use.

Innovair Nexthaler should be avoided in patients with known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It is also contraindicated in individuals who experience severe paradoxical bronchospasm after inhalation or who have uncontrolled cardiovascular disease without medical supervision.